Biotech · Public company · Menlo Park, CA, US
AN2 Therapeutics, Inc.
Ticker ANTX · SEC CIK 0001880438
Track this companyFree. Adds AN2 Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline4
- EpetraborolePhase 3 · MAC Lung DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- EpetraborolePhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- EpetraborolePhase 1 · Renal InsufficiencyClinicalTrials.gov · fetched Nov 12, 2026
- MoxifloxacinPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Epetraborole in Patients With Mycobacterium Abscessus Lung DiseasePHASE2 · RECRUITING · started Mar 30, 2026ClinicalTrials.gov NCT07301320 · fetched Nov 12, 2026
- A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult SubjectsPHASE1 · COMPLETED · started Jun 5, 2023ClinicalTrials.gov NCT05995444 · fetched Nov 12, 2026
- Study of Epetraborole in Patients With Treatment-refractory MAC Lung DiseasePHASE2_PHASE3 · TERMINATED · started May 20, 2022ClinicalTrials.gov NCT05327803 · fetched Nov 12, 2026
- A Study of Epetraborole Tablets in Subjects With Degrees of Renal FunctionPHASE1 · COMPLETED · started Feb 21, 2022ClinicalTrials.gov NCT05283746 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 20, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 17, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 17, 2026 · fetched Nov 12, 2026
NIH awards2
- Development of a Novel Therapeutic for MelioidosisFiscal year 2025 · $456.8KNIH RePORTER 75N93022C00059-P00008-9999-1 · fetched Nov 12, 2026
- Development of a Novel Therapeutic for MelioidosisFiscal year 2024 · $3.8MNIH RePORTER 75N93022C00059-P00004-9999-1 · fetched Nov 12, 2026